Middletown Life

Author: Levicept

Levicept Announces The Lancet Publication of LEVI-04 Phase II Clinical Trial Results, Showing Significant Reduction in Pain and Symptoms of Osteoarthritis

March 30, 2026
Levicept Announces the Appointment of James Sandy as Chief Development Officer

February 12, 2026
Levicept Announces FDA Acceptance of IND Application for LEVI-04, a Potentially Disease-Modifying Treatment for Osteoarthritis

January 20, 2026